- Curia has completed a $4 million upgrade of two aseptic manufacturing suites at its Valladolid, Spain, facility.
- The upgrades include fully closed-system processing and new equipment aligned with EU GMP Annex 1 standards.
Curia Global has completed a $4 million upgrade of two aseptic manufacturing suites at its facility in Valladolid, Spain, expanding its sterile manufacturing capabilities in line with EU GMP Annex 1 requirements.
The upgrade centered on transitioning the facility to a fully closed manufacturing system intended to improve process and product integrity while reducing microbiological risk throughout production. Curia also upgraded core systems and equipment, including the installation of advanced isolators, HVAC systems, pharmaceutical utilities, automation systems, and sterilization-in-place processes.
According to the company, the investment is designed to support increasing customer demand for sterile manufacturing and more complex sterile drug products. The Valladolid site will provide additional flexibility, contamination control, and manufacturing reliability for aseptic production programs.
“This investment at Valladolid reflects Curia’s commitment to delivering high-quality sterile manufacturing capabilities that align with the growth plans of our customers. These facility enhancements position us as a stronger partner when it comes to producing increasingly complex sterile products while maintaining the high standards of quality assurance that regulators and customers expect.”
Philip Macnabb, CEO of Curia
